Literature DB >> 24240551

Resource consumption and healthcare costs of acute coronary syndrome: a retrospective observational administrative database analysis.

Alessandro Roggeri1, Roberto Gnavi, Marco Dalmasso, Raffaella Rusciani, Massimo Giammaria, Monica Anselmino, Daniela Paola Roggeri.   

Abstract

The objective of this study was to estimate resource consumption and direct healthcare costs of patients with a first hospitalization for acute coronary syndrome (ACS) in 2008 in the Piedmont Region, Italy. Subjects hospitalized with a first episode of ACS in 2008 were selected from the regional hospital discharge database. All hospitalizations, drug prescriptions, and outpatient episodes of care in the 12 months following discharge were considered to estimate resource consumption and direct healthcare costs from the Piedmont Regional Health Service perspective. The analysis was carried out separately for ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), and unstable angina (UA) populations. In the accrual period, 7765 subjects (1.75‰ of the total population) were hospitalized for ACS (64.2% men). The average age was 66.5 for men and 75.4 for women. The average in-hospital mortality was 6.5% (n = 508). The total ACS population was classified as: STEMI 45.2%, NSTEMI 29.4%, and UA 25.4%. The average yearly costs per patient alive at the end of follow-up (n = 6851) were 14,160.8&OV0556; (18,678.7 USD): 83.9% for inpatient admissions [11,881.2&OV0556; (15,671.8 USD)], 9.3% for drugs [1311.6&OV0556; (1730.1 USD)], 5.0% for diagnostic and therapeutic procedures and outpatient visits [708.2&OV0556; (934.1 USD)], and 1.8% for 1-day hospital stays [259.8&OV0556; (342.7 USD)]. The average yearly direct healthcare costs by ACS event were 14,984.5&OV0556; (19,765.2 USD) for STEMI, 14,554.1&OV0556; (19,197.4 USD) for NSTEMI, and 12,481.5&OV0556; (16,463.6 USD) for UA. In each subpopulation, costs were significantly higher for men than for women. ACS imposes a significant burden in terms of morbidity and mortality and generates major public health service costs.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24240551     DOI: 10.1097/HPC.0b013e3182a78c06

Source DB:  PubMed          Journal:  Crit Pathw Cardiol        ISSN: 1535-2811


  5 in total

1.  A Systematic Review of Direct Cardiovascular Event Costs: An International Perspective.

Authors:  Steve Ryder; Kathleen Fox; Pratik Rane; Nigel Armstrong; Ching-Yun Wei; Sohan Deshpande; Lisa Stirk; Yi Qian; Jos Kleijnen
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

2.  Healthcare costs associated with cardiovascular events in patients with hyperlipidemia or prior cardiovascular events: estimates from Swedish population-based register data.

Authors:  S Hallberg; S R Gandra; K M Fox; J Mesterton; J Banefelt; G Johansson; L-Å Levin; P Sobocki
Journal:  Eur J Health Econ       Date:  2015-06-16

3.  All-cause mortality, cardiovascular events, and health care costs after 12 months of dual platelet aggregation inhibition after acute myocardial infarction in real-world patients: findings from the Platelet-aggregation Inhibition: Persistence with treatment and cardiovascular Events in Real world (PIPER) study.

Authors:  Luca Degli Esposti; Valentina Perrone; Chiara Veronesi; Stefano Buda; Roberta Rossini
Journal:  Vasc Health Risk Manag       Date:  2018-11-20

4.  Predictors of high-cost hospitalization in the treatment of acute coronary syndrome in Asia: findings from EPICOR Asia.

Authors:  Stephen Jan; Stephen W-L Lee; Jitendra P S Sawhney; Tiong K Ong; Chee Tang Chin; Hyo-Soo Kim; Rungroj Krittayaphong; Vo T Nhan; Stuart J Pocock; Ana M Vega; Nobuya Hayashi; Yong Huo
Journal:  BMC Cardiovasc Disord       Date:  2018-07-04       Impact factor: 2.298

5.  Issue with Evaluating Costs Over Time in a Context of Medical Guideline Changes: An Example in Myocardial Infarction Care Based on a Longitudinal Study from 1997 to 2018.

Authors:  Tania Villeneuve; Xavier Trudel; Mahée Gilbert-Ouimet; Jacinthe Leclerc; Alain Milot; Hélène Sultan-Taïeb; Chantal Brisson; Jason Robert Guertin
Journal:  Clinicoecon Outcomes Res       Date:  2022-01-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.